He has 20 years of healthcare experience on Wall Street including alternative investments, research and marketing in both the public and private markets. He co-founded Black Diamond Research, LLC (“BDR”), an independent sell-side research firm specializing in healthcare investing, financing and operations, serving the institutional investing community at large.

Patrick served as VP of Business Development and Investor Relations as well as a strategic consultant for Kinex Pharmaceuticals, a biotechnology firm focused on next-generation therapies in oncology and immunology (now traded on NASDAQ: ATNX). He also has served as an advisor to CHD Biosciences, a novel antimicrobial company. Mr. Gallagher serves on the board of directors of BioSig Technologies, Inc., NASDAQ listed a medical device company that is developing a proprietary technology platform in the electrophysiology space, Cingulate Therapeutics a therapeutics company with a novel drug delivery platform, and Evermore Global a global special situations money manager.

Mr. Gallagher is also a Managing Partner at Laidlaw Venture Partners dba Laidlaw & Company (UK) Ltd. and is part of the Investment Banking Healthcare Team.